Dillon Smith

BioGX, Inc. is a global molecular diagnostics company that has been focused on the health and safety of communities all over the world from its inception in 2007, originally developing tests for Water Quality, Food Safety and Pharma Quality Control. The company has since grown into a formidable contender in the molecular diagnostics industry, leading the way for simple yet superior molecular diagnostics testing. Headquartered in Alabama, USA, BioGX’s American footprint allows for the manufacture of custom-designed, platform agnostic Sample-Ready™ reagents for Laboratory Developed Tests (USA only). Using real-time PCR, BioGX makes molecular testing easy for labs with its novel Sample-Ready™ approach to LDTs, which enables a lab to specify its choice of test and receive a high-performance mix of all the necessary reagents, primers and probes, lyophilized and in one tube without the need for refrigeration. The proprietary Sample-Ready™ technology is at the core of the company’s worldwide offerings across clinical, food safety, pharma and water quality testing. Wholly owned subsidiary, BioGX BV, is located in Amsterdam, The Netherlands and boasts a large portfolio of CE-IVD marked tests, spread across a wide variety of infectious diseases ranging from COVID-19, respiratory, sexual health, enteric pathogens, drug resistance, meningitis, transplant, and tropical disease. With our Global Partnership Initiative, we can supply the rest of the world with our products, fast and effectively. All BioGX reagents are fine-tuned to ensure the highest performance in any lab setting, even outer space, where our products are currently used on the International Space Station. Through continuous innovation our team of scientists aim to make RT-PCR as simple, robust and efficient for laboratories all over the world.